Takeda
Takeda Pharmaceutical Company Limited, commonly known as Takeda, is a leading global biopharmaceutical firm headquartered in Japan. Founded in 1781, Takeda has evolved into a prominent player in the pharmaceutical industry, with a strong presence in regions such as North America, Europe, and Asia. The company focuses on key therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases, offering innovative treatments that address unmet medical needs. Takeda is renowned for its commitment to research and development, with a robust pipeline of biologics and small molecules. Notable achievements include its strategic acquisitions and partnerships that have bolstered its market position, making it one of the largest pharmaceutical companies in the world. With a dedication to patient-centric solutions, Takeda continues to lead in delivering unique therapies that improve health outcomes globally.
DitchCarbon Score
How does Takeda's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Takeda's score of 80 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Takeda's reported carbon emissions
In 2023, Takeda Pharmaceutical Company reported total greenhouse gas emissions of approximately 4,265,000,000 kg CO2e. This figure includes 279,000,000 kg CO2e from Scope 1 emissions, 33,000,000 kg CO2e from Scope 2 emissions (market-based), and a significant 3,953,000,000 kg CO2e from Scope 3 emissions, which encompass the majority of their carbon footprint. Takeda has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2040. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 65% by FY2030 from a FY2016 baseline, and to cut Scope 3 emissions by 25% by FY2030 from a FY2022 baseline. Long-term goals include a 90% reduction in Scope 1 and 2 emissions by FY2035 and a 90% reduction in Scope 3 emissions by FY2040. These targets align with the Science Based Targets initiative (SBTi) and reflect Takeda's commitment to sustainable practices within the pharmaceutical industry. The company is also focused on ensuring that 67% of its suppliers, covering significant emissions categories, will have science-based targets by 2024.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 700,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 372,244,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 3,700,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Takeda is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
